Zydus Cadila gets USFDA nod for blood pressure drug
With the latest approvals from the USFDA, the group now has more than 140 approvals and has so far filed over 300 abbreviated new drug applications.
BLOOD PRESSURE DRUG
-
Glenmark recalls 6,528 bottles of blood pressure drug in US
As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
-
Japan's Takeda flags profit slide as it bolsters drug pipeline
-
Pfizer recalls some batches of blood pressure drug over carcinogen presence
-
Pfizer recalls some lots of blood pressure drug due to potential carcinogen
-
Dr Reddy's launches drug to treat high blood pressure, heart failure in US market
-
Lupin posts third-quarter loss on charge related to blood pressure drug
-
Teva to recall certain blood pressure medicine in U.S.
-
Zydus Cadila gets USFDA nod to market 2 drugs
-
Zydus Cadila gets USFDA nod to sell BP lowering drug
Advertisement
More in BLOOD PRESSURE DRUG
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
